Skip to main content
Year archive

Immunovia — 2019 filings

All 45 regulatory filings released by Immunovia (IMMNOV) in 2019, sourced directly from the official regulator.

45 Filings
2019 Period
2019 filings (45)
Filing Released Lang
Immunovia uppnår viktig milstolpe genom framgångsrikt slutförande av IMMray® PanCan-d Commercial Test Model Study med hög noggrannhet
Regulatory Filings
2019-12-19 Swedish
Immunovia Announces Achieving a Major Milestone with the Successful Completion of the IMMray[TM] PanCan-d Commercial Test Model Study with High Accuracy
Earnings Release Q3 2019
2019-12-19 English
Immunovia stärker ledningsteamet inför sin kommersiella lansering av IMMray® PanCan-d
Board/Management Information
2019-12-09 Swedish
Immunovia Strengthens Management Team Ahead of its Commercial Launch of IMMray™ PanCan-d
Board/Management Information
2019-12-09 English
Immunovia continues with next stage of the Lung Cancer Project together with Global Pharma Partner
Regulatory Filings
2019-11-29 English
Immunovia fortsätter med nästa fas i lungcancerprojektet tillsammans med global läkemedelspartner
Regulatory Filings
2019-11-29 Swedish
Correction: Immunovia Interim Report, January-September 2019
Interim / Quarterly Report 9M 2019
2019-11-08 English
Korrigerad version: Immunovia delårsrapport januari-september 2019
Interim / Quarterly Report 9M 2019
2019-11-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-08 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report 9M 2019
2019-11-08 English
Immunovia AB (Publ) nomination committee appointed for AGM 2020
Board/Management Information
2019-11-04 English
Valberedning utsedd inför årsstämma 2020 i Immunovia AB (Publ)
AGM Information
2019-11-04 Swedish
Uppdatering från Immunovia om dess pipelineprojekt inom reumatoid artrit samt meddelande om nytt samarbete
Regulatory Filings
2019-10-22 Swedish
Immunovia Provides an Update on its Rheumatoid Arthritis Pipeline Project and Announces New Collaboration
Regulatory Filings
2019-10-22 English
Immunovia Provides an Update on its Lung Cancer Pipeline Projects
Regulatory Filings
2019-10-02 English
Immunovia lämnar uppdatering om sina pågående lungcancerprojekt
Regulatory Filings
2019-10-02 Swedish
Immunovia Announces Company On Track with Commercial Test Model Study
Regulatory Filings
2019-09-30 English
Immunovia meddelar att Commercial Test Model Study fortskrider enligt plan
Regulatory Filings
2019-09-30 Swedish
Immunovia and world-class teaching hospital finalize agreement for collection of pancreatic cancer blood samples for IMMray™ PanCan-d
Regulatory Filings
2019-09-12 English
Immunovia och universitetssjukhus i världsklass slutför avtal om insamling av blodprov i bukspottkörtelcancer för IMMray® PanCan-d
Regulatory Filings
2019-09-12 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-23 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report H1 2019
2019-08-23 English
Erlangen University Hospital and Immunovia enter into a collaboration agreement for the collection of pancreatic cancer blood samples for the final steps of IMMray™ PanCan-d development
Regulatory Filings
2019-07-17 English
Erlangens universitetssjukhus och Immunovia ingår samarbetsavtal om insamling av blodprov vid bukspottkörtelcancer för de sista stegen i IMMray® PanCan-d utvecklingen
Regulatory Filings
2019-07-17 Swedish
Resultat från optimeringsstudien IMMray™ PanCan-d presenteras på PancreasFest 2019
Regulatory Filings
2019-07-11 Swedish
Results on the IMMray™ PanCan-d optimization study to be presented at PancreasFest 2019
Earnings Release FY 2019
2019-07-11 English
Immunovias VD Mats Grahn säljer 48 000 Immunovia-aktier till en svensk institutionell investerare
Director's Dealing
2019-06-19 Swedish
Immunovia's CEO Mats Grahn sells 48,000 Immunovia shares to a Swedish institutional investor
Director's Dealing
2019-06-19 English
Immunovia announces excellent results across all symptomatic risk groups from IMMray™ PanCan-d optimization work
Earnings Release FY 2019
2019-06-03 English
Immunovia meddelar utmärkta resultat för samtliga symptomatiska riskgrupper från optimeringsarbetet med IMMray® PanCan-d
Regulatory Filings
2019-06-03 Swedish
Immunovia meddelar att optimeringsarbetet fortskrider i tid och enligt plan
Regulatory Filings
2019-04-29 Swedish
Immunovia announces optimization work is progressing on-schedule and according to plan
Earnings Release Q1 2019
2019-04-29 English
Immunovia Stämmokommuniké
AGM Information
2019-04-26 Swedish
Immunovia - Report from AGM
AGM Information
2019-04-26 English
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-24 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Q1 2019
2019-04-24 English
Immunovia and University College of London sign agreement to extendvalidation studies of IMMray™ PanCan-d for early signs and symptoms
Regulatory Filings
2019-04-08 English
Immunovia och University College of London tecknar avtal om att utöka valideringsstudierna av IMMray® PanCan-d för tidiga tecken och symptom
Regulatory Filings
2019-04-08 Swedish
Annual Report 2018
Annual Report FY 2018
2019-04-04 English
KALLELSE TILL ÅRSSTÄMMA I IMMUNOVIA AB
AGM Information
2019-03-20 Swedish
Annual Report 2018
Annual Report FY 2018
2019-03-04 Swedish
Immunovia tillhandahåller uppdatering av optimeringsarbetet för att uppnå förväntad prestanda för kommersialisering av IMMray® PanCan-d
Earnings Release FY 2019
2019-03-04 Swedish
Immunovia provides an update on the optimization work to meet the expected performance for commercialization of IMMray™ PanCan-d
Regulatory Filings
2019-03-04 English
Earnings Release 2018
Earnings Release FY 2018
2019-02-14 Swedish
Annual Report 2018
Annual Report FY 2018
2019-02-14 English